Sorriso Pharmaceuticals Inc. Press Releases

• Published on September 3, 2024 - 13:00 GMT

  Sorriso Pharmaceuticals Completes Enrollment in Phase 1b Clinical Trial of Patients with Ulcerative Colitis

  Innovative Oral Dual-Acting Biologic Targeting TNFα and IL-23 p19 in Ulcerative Colitis SALT LAKE CITY, UT, UNITED STATES, September 3, 2024 /⁨EINPresswire.com⁩/ -- Sorriso Pharmaceuticals, a biopharmaceutical company developing novel oral antibodies for …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on May 17, 2024 - 13:00 GMT

  Sorriso Pharmaceuticals Announces First Patients Dosed in Phase 1b Clinical Trial for Patients with Ulcerative Colitis

  Study to Evaluate SOR102, a Novel Oral Dual-Acting Antibody Targeting TNF⍺ and IL-23 (p19) for Inflammatory Bowel Disease SALT LAKE CITY, UT, UNITED STATES, May 17, 2024 /⁨EINPresswire.com⁩/ -- Sorriso Pharmaceuticals, a biopharmaceutical company …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on November 1, 2023 - 12:00 GMT

  Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102

  First-in-Human Study of Novel Oral Dual-Acting Antibody in Development for Treatment of Patients with Inflammatory Bowel Disease SALT LAKE CITY, UT, UNITED STATES, November 1, 2023 /⁨EINPresswire.com⁩/ -- Sorriso Pharmaceuticals, a biopharmaceutical …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...